| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |